Cassava Sciences Inc vs KraneShares Electric Vehicles and Future Mobility — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while KraneShares Electric Vehicles and Future Mobility trades at $27.56 (market cap $72.36M). The key difference: KraneShares Electric Vehicles and Future Mobility is the larger of the two by market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 5,034). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and KraneShares Electric Vehicles and Future Mobility for 46 Days on average.
| FLNA | KARS | |
|---|---|---|
Market Cap | $39.40M | $72.36M |
Volume | 759,018 | 5,034 |
Sector | Health | Sector/Thematic |
52-Week High | $4.64 | $38.01 |
52-Week Low | $0.68 | $27.25 |
Typical Hold Time | 37 Days | 46 Days |
Enterprise Value | -$43.28M | — |
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →